ASCO 2019 | CHECKMATE 920: nivolumab plus ipilimumab for renal cell cancer

Hamid Emamekhoo

Hamid Emamekhoo, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, discusses the CHECKMATE 920 (NCT02982954) study investigating the safety of nivolumab in combination with ipilimumab in subjects with previously untreated advanced or metastatic renal cell cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics